4502 — Takeda Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥6tn
- ¥11tn
- ¥4tn
- 30
- 57
- 44
- 37
R2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,097,224 | 3,291,188 | 3,197,812 | 3,569,006 | 4,027,478 |
Cost of Revenue | |||||
Gross Profit | 1,445,495 | 2,201,424 | 2,203,504 | 2,462,160 | 2,783,406 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,874,647 | 3,193,729 | 2,596,860 | 3,123,808 | 3,494,185 |
Operating Profit | 222,577 | 97,459 | 600,952 | 445,198 | 533,293 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 127,612 | -60,754 | 366,235 | 302,571 | 375,090 |
Provision for Income Taxes | |||||
Net Income After Taxes | 135,080 | 44,290 | 376,171 | 230,166 | 317,038 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 135,192 | 44,241 | 376,005 | 230,059 | 317,017 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 135,192 | 44,241 | 376,005 | 230,059 | 317,017 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 112 | 107 | 129 | 194 | 211 |
Dividends per Share |